文献速递肿瘤 PET/CT

11C-乙酸盐与18F-氟胆碱PET/CT及PET/MRI对早期复发前列腺癌再分期的长期对照研究结果

Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2017-01-01

33例根治性前列腺切除术后(10例,PSA≤3 ng/mL)、原发放疗后(8例,PSA≤5 ng/mL)或根治性前列腺切除+挽救性放疗后(15例)复发的前列腺癌患者,随机顺序接受11C-乙酸盐(ACE)与18F-氟胆碱(FCH)PET-CT(29例)或PET-MRI(4例)检查。ACE检出率66%、FCH 60%,结果一致率79%(26/33);中位随访41个月后,ACE与FCH分别正确识别53%(17/32)与47%(15/32)的复发部位,分别有11例(34.4%)与9例(28%)患者的治疗方案因PET结果而改变。

要点

  • ACE检出率66%高于FCH的60%,两者结果一致率79%(26/33)。
  • 中位随访41个月,ACE正确识别复发部位53%(17/32),FCH为47%(15/32)。
  • ACE与FCH PET分别使11例(34.4%)与9例(28%)患者的治疗方案发生改变。

核心结论

  • 在早期复发前列腺癌中,ACE与FCH差异较小,主要限于淋巴结分期且多位于腹膜后区域。
  • 随访期间约半数PET阳性病灶被证实为真阳性。
  • 约三分之一患者的治疗方案受到ACE或FCH PET检查结果的影响。

研究设计与样本

  • 33例根治性前列腺切除术后(n=10,PSA≤3 ng/mL)、原发放疗后(n=8,PSA≤5 ng/mL)或根治性前列腺切除+挽救性放疗后(n=15)复发的前列腺癌患者。
  • 患者以随机顺序接受ACE与FCH PET-CT(n=29)或PET-MRI(n=4)检查,两次检查间隔0至21天。

主要发现

  • ACE检出率为66%,FCH检出率为60%。
  • 两种检查结果一致者占79%(26/33),不一致者占21%(腹膜后5例、直肠旁1例、髂外淋巴结1例)。
  • 中位随访41个月(n=32,1例失访)后,ACE与FCH分别正确识别53%(17/32)与47%(15/32)患者的复发部位,其中2例M1a患者为ACE阳性/FCH阴性。
  • 32例患者中有6例复发部位未被定位。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aims of this study were to assess the intraindividual performance of F-fluorocholine (FCH) and C-acetate (ACE) PET studies for restaging of recurrent prostate cancer (PCa), to correlate PET findings with long-term clinical and imaging follow-up, and to evaluate the impact of PET results on patient management. METHODS: Thirty-three PCa patients relapsing after radical prostatectomy (n = 10, prostate-specific antigen [PSA] ≤3 ng/mL), primary radiotherapy (n = 8, prostate-specific antigen ≤5 ng/mL), or radical prostatectomy + salvage radiotherapy (n = 15) underwent ACE and FCH PET-CT (n = 29) or PET-MRI (n = 4) studies in a randomized sequence 0 to 21 days apart. RESULTS: The detection rate for ACE was 66% and for FCH was 60%. Results were concordant in 79% of the cases (26/33) and discordant in 21% (retroperitoneal, n = 5; pararectal, n = 1; and external iliac nodes, n = 1). After a median FU of 41 months (n = 32, 1 patient lost to FU), the site of relapse was correctly identified by ACE and FCH in 53% (17/32) and 47% (15/32) of the patients, respectively (2 M1a patients ACE+/FCH-), whereas in 6 of 32 patients the relapse was not localized. Treatment approach was changed in 11 (34.4%) of 32 patients and 9 (28%) of 32 patients restaged with ACE and FCH PET, respectively. CONCLUSIONS: In early recurrent PCa, ACE and FCH showed minor discrepancies, limited to nodal staging and mainly in the retroperitoneal area, with true positivity of PET findings confirmed in half of the cases during FU. Treatment approach turned out to be influenced by ACE or FCH PET studies in one third of the patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lamanna G, Tabouret-Viaud C, Rager O, et al. Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer. Clin Nucl Med. 2017. PMID: 28240662. doi:10.1097/RLU.0000000000001609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。